Enzalutamide resistance remains a key challenge in the treatment of advanced prostate cancer (PCa), as clinical efficacy is frequently hindered by acquired resistance. While reactivation of AR signaling including AR splice variants, has been extensively studie... ...

请注册登录后继续浏览